Richard L. Schilsky

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

  JCO Precision Oncology · 2026-04-01

• Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

  JCO Precision Oncology · 2025-10-01

• 942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

  Annals of Oncology · 2025-09-01

• Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies

  Clinical Trials · 2025-08-21

• Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

  European Journal of Cancer · 2025-08-05 · 1 citations

• Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study

  npj Precision Oncology · 2025-07-03 · 1 citations

• Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with <i>ERBB2/3</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

  Journal of Clinical Oncology · 2025-05-28

• Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer

  The Lancet Oncology · 2025-05-01 · 7 citations

• Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with <i>ATM</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

  Cancer Research · 2025-04-25

• Abstract LB373: Structuring the unstructured: How protocol quality and precision drive clinical trial completion

  Cancer Research · 2025-04-25

• Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with <i>FGFR2</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

  Cancer Research · 2025-04-25

• Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

  ESMO Open · 2025-04-10 · 11 citations

• Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients

  Oncotarget · 2025-03-12 · 3 citations

• Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

  Journal of Clinical Oncology · 2025-01-27 · 3 citations

• Optimizing public-private partnerships to support clinical cancer research

  JNCI Journal of the National Cancer Institute · 2024-12-12 · 6 citations

• Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

  JCO Precision Oncology · 2024-10-01 · 4 citations

• Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

  Nature Communications · 2024-08-22 · 1 citations

• Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

  Nature Communications · 2024-07-11 · 8 citations